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Abstract
Background. Autosomal dominant polycystic kidney
disease (ADPKD) is characterized by dysregulated
tubular epithelial cell growth, resulting in the forma-
tion of multiple renal cysts and progressive renal
failure. To date, there is no effective treatment for
ADPKD. The mammalian target of rapamycin
(mTOR) is an atypical protein kinase and a central
controller of cell growth and proliferation. We
examined the effect of the mTOR inhibitor sirolimus
(rapamycin) on renal functional loss and cyst progres-
sion in the Han:SPRD rat model of ADPKD.
Methods. Five-week-old male heterozygous cystic
(Cy/þ) and wild-type normal (þ/þ) rats were adminis-
tered sirolimus (2mg/kg/day) orally through the
drinking water for 3 months. The renal function was
monitored throughout the treatment phase, and rats
were sacriﬁced thereafter. Kidneys were analysed
histomorphometrically, and for the expression and
phosphorylation of S6K, a well-characterized target of
mTOR in the regulation of cell growth.
Results. The steady increase in BUN and creatinine
in Cy/þ rats was reduced by 39 and 34%, respectively
with sirolimus after 3 months treatment. Kidney
weight and 2-kidney/total body weight (2K/TBW)
ratios were reduced by 34 and 26% in sirolimus-treated
Cy/þ rats. Cyst volume density was also reduced by
18%. Of importance, Cy/þ rats displayed enhanced
levels of total and phosphorylated S6K. Sirolimus
effectively reduced total and phosphorylated levels
of S6K.
Conclusion. We conclude that oral sirolimus markedly
delays the loss of renal function and retards cyst
development in Han:SPRD rats with ADPKD.
Our data also suggest that activation of the S6K
signalling pathway plays an important role in the
pathogenesis of PKD. Sirolimus could be a useful drug
to retard progressive renal failure in patients with
ADPKD.
Keywords: ADPKD; Han:SPRD rats; mTOR;
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Introduction
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common form of renal cystic
disease, affecting all ethnic groups worldwide, with an
incidence of 1 in 500 to 1 in 1000. The disease accounts
for up to 10% of all patients requiring renal replace-
ment therapy. Affected individuals usually present
in the 3rd and 4th decade of life, progressing to end-
stage renal disease (ESRD) within 5–10 years after the
development of renal insufﬁciency [1].
The disease is characterized by the progressive
development of ﬂuid-ﬁlled cysts in the kidney. The
renal cysts originate from the epithelia of the nephrons
and are lined by a single layer of cells that have a
higher rate of cellular growth and proliferation.
Various abnormalities in gene expression, ﬂuid secre-
tion, apoptosis and extracellular matrix production
have been described in ADPKD [2]. PKD1 and PKD2
encode for the proteins polycystin-1 and polycystin-2,
and various mutations in these genes are linked to the
occurrence of ADPKD [3–6]. How defects in these
genes lead to the massive cyst growth in patients with
ADPKD is being investigated [7].
Currently, there is no speciﬁc treatment for PKD
other than supportive care and blood pressure control.
Usually dialytic treatment or renal transplantation
Correspondence and offprint requests to: Prof. Dr Rudolf P.
Wu¨thrich, Renal Division, University Hospital, Ra¨mistrasse 100,
8091 Zu¨rich, Switzerland. Email: rudolf.wuethrich@usz.ch
 The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
becomes necessary when the disease has progressed
to end-stage renal failure. There is signiﬁcant interest
in searching for speciﬁc drugs which decrease or halt
the progression of cyst development, thus slowing renal
functional deterioration and preventing the develop-
ment of ESRD [8–10].
The Han:SPRD rat is a well-known model of
ADPKD, although the gene defect has not been
identiﬁed yet [11]. Recently, the drug rapamycin
(sirolimus) – an inhibitor of the mammalian target of
rapamycin (mTOR) – was found to signiﬁcantly inhibit
cyst growth in the Han:SPRD rat [12]. The protein
kinase mTOR has emerged as a major effector of cell
growth and proliferation via the regulation of protein
synthesis. mTOR controls protein synthesis through
a number of downstream targets, some of which are
phosphorylated directly by mTOR, while others are
phosphorylated indirectly, and could be dysregulated
in ADPKD.
The mTOR inhibitor sirolimus is an immunosup-
pressant drug with antiproliferative and growth
inhibiting effects [13,14]. It is used clinically in
recipients of renal allografts to prevent transplant
rejection. It is also used in coated stents to prevent
coronary artery re-stenosis after angioplasty [15]. Very
recently, sirolimus has shown clinical effectiveness in
kidney transplant recipients with Kaposi’s sarcoma
[16]. We hypothesized that mTOR and its downstream
cell growth regulatory proteins are dysregulated in
PKD, and that sirolimus could be an effective oral drug
to inhibit cyst progression. We therefore used the
Han:SPRD rat model of ADPKD [11] to test the effect
of oral sirolimus (Rapamune) on loss of renal function
and cyst progression. We also examined the activity
of the mTOR downstream target S6K (p70S6K) [17] in
these ADPKD rats and tested the effect of sirolimus on
this effector protein.
Subjects and methods
Animals
The study was conducted in heterozygous (Cy/þ) and nor-
mal littermate control (þ/þ) Han:SPRD rats. Only male rats
were used since the disease progresses faster in male compared
with female rats. A colony of Han:SPRD rats was established
in our animal care facility from breeding pairs that were
obtained from the Rat Resource & Research Center
(Columbia, MO, USA). The study protocol was approved
by the regulatory commission for animal studies, a local
government agency. Rats had free access to tap water and
standard rat diet.
Study drug
Rapamune oral solution (1mg/ml) was kindly provided by
Wyeth-AHP (Schweiz) AG, Switzerland.
Experimental protocol
Male Cy/þ and þ/þ rats were weaned and were then treated
at 5 weeks of age (n¼ 12) with 2mg/kg/day sirolimus.
Additional male Cy/þ andþ/þ rats (n¼ 16) were not treated,
and they served as controls. The drug was administered in the
form of Rapamune oral solution (Wyeth) in the drinking
water for 3 months. Drinking bottles were protected from
light with aluminum foil and were changed every 2 days.
The concentration of sirolimus (Rapamune oral stock
solution 1mg/ml) was adjusted according to rat body
weight. Blood was drawn from the tail veins every month.
After 3 months treatment, rats were anaesthetized with
isoﬂurane, and kidneys were removed, decapsulated and
weighed. Slices of each kidney were preserved in 4%
paraformaldehyde and embedded in parafﬁn for histological
examinations. Additional slices were snap frozen in liquid
nitrogen and used for protein extraction.
Blood chemistry
Blood was collected in lithium-heparin tubes and centrifuged
at 4C. Plasma was stored at 20C, and was analysed later
for blood urea nitrogen (BUN) and creatinine using kinetic
color test and the modiﬁed Jaffe´ method, respectively. Blood
for sirolimus levels was collected under the same conditions,
but using EDTA tubes and analysed using HPLC-mass
spectroscopy. All samples were analysed at the Institute
for Clinical Chemistry, University Hospital (Zu¨rich,
Switzerland).
Histology
Mid-transversal slices of the kidney, about 2mm-thick, were
ﬁxed by immersion in phosphate-buffered 4% paraformalde-
hyde, dehydrated in alcohol series and embedded in parafﬁn.
Three micrometer thick sections were stained with the
periodic acid-Schiff (PAS) technique. The cyst volume density
(CVD) was evaluated in these sections by morphometry,
using the technique of point counting [18].
To avoid subjective sampling biases, micrographs for
morphometry were taken according to an invariable protocol.
At the magniﬁcation used (Zeiss Plan-Neoﬂuar 10/0.30), the
diameter of the ﬁeld of view was close to the thickness of the
renal cortex in healthy rats. The ﬁrst micrograph was taken as
the ﬁeld was positioned on one extremity of the horseshoe-
shaped cortex. For further sampling, the microscope stage
was moved clockwise by steps of one ﬁeld diameter, while
the surface of the kidney remained at the limit of the ﬁeld.
A micrograph was made at every second step. A total of 4–6
micrographs was obtained for one section. One section was
evaluated per rat. The pixel size of the micrographs was
1300 1030 (1.34 mm/pixel). The cyst volume density of cysts
was evaluated by point counting. An orthogonal grid with
a line spacing of 150 pixels was used. The person responsible
for morphologic documentation and for morphometry was
blinded to the experimental groups.
Analysis of S6K activity
The amount of total and phosphorylated S6K was assessed
by immunoblotting, using speciﬁc antibodies. Samples of
kidney tissue were snap-frozen in liquid nitrogen and stored at
80C. On the day of immunoblotting, ice-cold lysis buffer
was prepared. The lysis buffer consisted of 50mM Tris base,
pH 7.4; 150mM NaCl; 1% deoxycholate; 1% SDS; and 1%
Triton X-100. Immediately before use, the lysis buffer was
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supplemented with 1mM PMSF, 10 mg/ml aprotinin,
10mg/ml leupeptin, and protease and phosphatase inhibitor
cocktail. Each sample was homogenized in this buffer with
a Dounce homogenizer. The protein concentration of each
sample was measured.
SDS-PAGE sample buffer was added to the extracts.
Extracts were heated to 90C for 5min for denaturation.
A total of 30 mg protein was loaded per lane for standard
SDS-PAGE (7.5%), and Western analysis. The following
antibodies were used for detection: sc-230 (St Cruz
Biotechnology, Inc., Santa Cruz, CA, USA; detects S6K),
#9205 and #9204 (Cell Signaling Technology, Inc., Beverly,
MA, USA; detect S6K phosphorylated on Thr389 and
Thr 421/Ser424, respectively), and MAB 1501 (Chemicon,
Temecula, CA, USA; detects actin). For signal detection,
horseradish peroxidase-conjugated secondary antibodies
and SuperSignal Femto/Pico ECL kits were used (Pierce
Biotechnology, Rockford, IL, USA).
Statistical analysis
Data are presented as means±SD and were analysed by
one-way ANOVA with post-test according to Newman–
Keuls. A P-value of <0.05 was considered signiﬁcant.
Results
Judging by physical appearance, the treatment with
sirolimus was well tolerated. None of the 12 sirolimus-
treated rats died, and all 16 control rats survived.
Sirolimus blood levels were obtained in all treated
animals, and were between 0.5 and 1.9 mg/l. Figure 1
shows that body weight increased steadily in untreated
and sirolimus treated Cy/þ and þ/þ rats. Treatment
with sirolimus did not signiﬁcantly change body weight
after 3 months of treatment (3.3% in þ/þ and 11%
in Cy/þ rats).
Renal functional loss is inhibited with sirolimus
Figure 2 demonstrates that the BUN and creatinine
levels remained within normal limits in þ/þ rats but
increased progressively in untreated Cy/þ rats. BUN
and creatinine levels also increased in sirolimus-treated
Cy/þ rats, but to a lesser degree. After 3 months of
treatment, the average BUN level was 39% less in
sirolimus-treated Cy/þ rats (n¼ 7) compared with
untreated Cy/þ rats (n¼ 9) (45.6±4.2 vs 75.3±
16.9mg/dl; P<0.001), and creatinine levels were 34%
less (0.89±0.13 vs 1.34±0.24mg/dl; P<0.001). This
demonstrates that sirolimus effectively inhibited the
loss of renal function in male Han:SPRD rats.
Renal weight and cyst volume density
are reduced with sirolimus
Figure 3 shows that the increase in kidney weight was
effectively reduced in sirolimus-treated Cy/þ compared
with untreated Cy/þ rats. Treatment with sirolimus
resulted in a 34% lower kidney weight in Cy/þ rats.
Sirolimus treatment did not have a signiﬁcant effect
on kidney weight in wild-type þ/þ rats (Figure 3A).
We also determined the 2K/TBW ratios. Figure 3B
demonstrates that sirolimus reduced the 2K/TBW ratio
by 26% in Cy/þ rats.
Histological examination of the Han:SPRD kidneys
revealed a signiﬁcant reduction in cyst size in sirolimus-
treated Cy/þ rats compared with untreated Cy/þ
animals (Figure 4). A more detailed microscopical
examination revealed the presence of tubular cysts in
the cortex, and to a lesser extent in the outer medulla
of untreated Cy/þ kidneys. The inner medulla was
not affected. Cystic expansion of Bowman’s capsule
was observed in a few glomeruli. Mononuclear cell
inﬁltrates were observed focally in the peritubular
interstitium. This histopathological pattern was not
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Fig. 1. Weight gain (g) in the four animal groups at 1, 2, 3 and 4 months of age. Treatment with sirolimus was started at 5 weeks and did
not signiﬁcantly inﬂuence weight gain (ANOVA).
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affected qualitatively by sirolimus treatment in Cy/þ
kidneys. Untreated and sirolimus-treated wild-type
þ/þ kidneys showed no difference in histology (data
not shown).
The most signiﬁcant effect of sirolimus on kidney
histology was a signiﬁcant reduction of the cyst volume
density in the cortex of Cy/þ rats. Figure 5 demon-
strates that cyst volume density was 18% less in
sirolimus-treated Cyþ/rats (P<0.001). Since the refer-
ence volume for evaluation of volume density was the
total cortical volume and since sirolimus treatment
considerably reduced the increase of kidney weight
in Cy/þ rats, the effect of sirolimus on the cyst volume
density certainly underestimates its effect on the
absolute volume of cysts.
Total and phosphorylated levels of S6K
are enhanced in ADPKD rats
mTOR controls protein synthesis and cell growth by
phosphorylating and thereby activating the 70 kDa
ribosomal S6 kinase (S6K) [19]. Thus far it has not
been tested whether mTOR-S6K signalling is altered in
ADPKD, and whether the mTOR inhibitor sirolimus
affects ADPKD. We therefore examined S6K expres-
sion and phosphorylation in untreated and sirolimus-
treated Cy/þ rats. Figure 6 shows that total levels of
S6K are markedly increased in the kidneys of 4-month-
old Cy/þ Han:SPRD rats compared with wild-
type þ/þ rats. The level of expression of S6K was
effectively reduced in sirolimus-treated Cy/þ rats.
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Fig. 2. Blood urea nitrogen (BUN) (A) and serum creatinine (B) levels were measured monthly in all rats. The rise in BUN and creatinine
was signiﬁcantly reduced by sirolimus in Cy/þ rats.
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We then measured the activity of S6K by analysing
the mTOR-dependent phosphorylation of S6K at
threonine 389 and threonine 421/serine 424 [20–23].
Figure 5 shows that the phosphorylated forms of S6K
were undetectable in normal þ/þ kidneys, but mark-
edly enhanced in Cy/þ kidneys. Sirolimus effectively
reduced phosphorylation at Thr389 and Thr421/Ser424
of S6K in Cy/þ kidneys. Overall, there was an excellent
correlation between the histomorphometric ﬁndings
and the degree of S6K phosphorylation.
Discussion
The massive and spontaneous development of cysts
results in progressive deterioration of renal function
in male Han:SPRD rats. This leads to symptomatic
renal failure and premature death in these animals.
Here, we demonstrate that sirolimus, when given orally
for 3 months, signiﬁcantly improves renal function in
male Han:SPRD rats. Sirolimus treatment effectively
Fig. 4. Parafﬁn sections of kidneys of a wild-type, sirolimus-treated
(A), of a Cy/þ untreated (B) and of a Cy/þ sirolimus-treated rat
(C). Sirolimus reduced the kidney size, cyst volume and cyst density
markedly in Cy/þ rats. PAS staining. Bar length: 1.5mm.
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Fig. 3. The 2-kidney weights (2KWt) (A) and 2-kidney/total body
weight (2K/TBWt) ratios (B) were determined after 3 months of
treatment with sirolimus. Both parameters were signiﬁcantly
reduced by sirolimus in Cy/þ rats. *P<0.001 (Cy/þ untreated vs
þ/þ untreated); **P<0.001 (Cy/þ untreated vs Cy/þ sirolimus-
treated).
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Fig. 5. Cyst volume density (CVD) was massive in Cy/þ rats and
was signiﬁcantly decreased (18%) in sirolimus-treated Cy/þ rats.
*P<0.001 (Cy/þ untreated vs Cy/þ sirolimus-treated).
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controlled the massive increase in kidney weight in
Cy/þ rats and signiﬁcantly reduced the cyst volume
density. Our data conﬁrm and extend a very recent
report by Tao et al. [12]. They found that rapamycin,
when injected intraperitoneally for 5 weeks, improved
renal function and slowed cyst progression in the same
rat model of ADPKD.
We applied sirolimus by using the Rapamune oral
solution. This is the galenic form which is approved
to prevent graft rejection in renal transplant patients.
Using a 2mg/kg/day dose resulted in relatively low
blood levels in our animals (between 0.5 and 1.9 mg/l).
This indicates that the drug was absorbed poorly.
Despite these low levels, the therapeutic effect was
impressive. Tao et al. used a different preparation of
sirolimus at a 10-fold lower daily dose intraperitoneally
[12]. They did not measure blood levels, but judging
by the signiﬁcantly reduced body weight (22%) in
their rapamycin-treated rats it is likely that blood levels
were higher in their animals. The 3-month treatment
was well tolerated in our rats with no signiﬁcant effect
on body weight.
In the study by Tao et al., treatment with sirolimus
did not completely prevent progression of cystic disease
[12]. This was the case in our study also. However,
both studies show that the treatment with sirolimus
markedly retarded renal functional loss. In our study
we treated animals for an extended period of 3 months
and found a continued inhibitory effect on renal
functional loss and cystic expansion. More studies are
needed to determine whether mortality is reduced in
Han:SPRD rats by prolonging treatment with sirolimus
or other mTOR inhibitors.
Sirolimus is known to inhibit its molecular target
mTOR. As it was highly effective in Han:SPRD
rats, we hypothesize that the mTOR pathway is
dysregulated in the kidneys of these rats. mTOR
regulates a vast array of cellular functions, and
promotes cell growth and proliferation [19]. A well-
characterized function of mTOR in mammalian cells is
the upregulation of protein synthesis via S6K, a
direct substrate of mTOR. Phosphorylation of S6K
by mTOR enhances translation of certain mRNAs,
which play an important role in translation regulation,
increasing thereby the overall translation capacity of
cells [24].
We describe here for the ﬁrst time that total amounts
of S6K and activity of S6K (determined as phosphor-
ylation of S6K) are enhanced in the kidneys of
Han:SPRD rats with ADPKD and that this can be
reversed by the application of sirolimus. In an acute
renal failure model, it has been shown that activated
S6K is increased in rat kidneys, suggesting that this
signalling pathway is activated in other types of renal
injury [17]. The mechanisms which lead to the enhanced
expression and phosphorylation of S6K in cystic
kidneys of Han:SPRD need to be investigated further.
Our ﬁndings point to an important role of the mTOR
pathway in Han:SPRD. We hypothesize that there
could be an interaction between molecules which are
defective in Han:SPRD and the mTOR pathway in
the pathogenesis of cyst growth. The nature and the
importance of these interactions need to be investigated
in further studies.
In summary, we demonstrate that oral sirolimus
markedly inhibits the rapid deterioration of renal
function by inhibiting cyst growth in Han:SPRD rats
with ADPKD. We speculate that mTOR and its
downstream effector S6K play a critical role in the
pathogenesis of ADPKD. Further studies are in
progress to elucidate the mechanisms of the altered
expression and phosphorylation of these proteins,
and to examine the effect of mTOR inhibition in
other animal models of cystic kidney disease.
actin
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Fig. 6. SDS-PAGE and Western blot analysis from kidney protein extracts for total amounts of S6K, phosphorylated S6K (Thr389, and
Thr421/Ser424) and actin. Two representative animals were analyzed from each group. The amount of total and phosphorylated S6K was
markedly increased in Cy/þ kidneys (lanes 5 and 6), and this was effectively suppressed by sirolimus (lanes 7 and 8).
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